Статті в журналах: "Glycemic excursions"

1

Yong, Guangjin, Qian Jing, Qing Yao, Kechun Yang, and Xinhua Ye. "Changing Meal Sequence Affects Glucose Excursions in Gestational Diabetes Mellitus." Journal of Diabetes Research 2022 (July 21, 2022): 1–7. http://dx.doi.org/10.1155/2022/7083106.

Повний текст джерела

Анотація:

Studies on nutrient sequences during meals suggest that consuming carbohydrates last lowers postprandial glucose excursions more than consuming carbohydrates first. However, this phenomenon has not been studied in gestational diabetes mellitus (GDM). Ten women with GDM consumed the same caloric foods in different sequences over five successive days: (A) dish first, followed by carbohydrate and soup last; (B) carbohydrate first, followed by dish and soup last; (C) soup first, followed by dish and carbohydrate last; (D) three meals a day ad libitum; and (E) six meals a day as ad libitum. Continuous glucose monitoring (CGM) was used to assess diurnal glycemia. Decreases in mean glucose levels and the largest glucose levels in A were similar to group C. The peak glucose of breakfast and lunch in group B was more significant than in groups A and C. The B meal pattern showed more marked glycemic excursions than groups A and C. Increasing the number of meals reduced the peak glucose level and the glycemic excursions with the same total calories. Changing meal sequences or increasing the number of meals may reduce glycemic excursions in GDM. Our trial was registered retrospectively and the trial registration number is ChiCTR2200057044.

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Chang, Courtney R., Monique E. Francois, and Jonathan P. Little. "Restricting carbohydrates at breakfast is sufficient to reduce 24-hour exposure to postprandial hyperglycemia and improve glycemic variability." American Journal of Clinical Nutrition 109, no. 5 (April 9, 2019): 1302–9. http://dx.doi.org/10.1093/ajcn/nqy261.

Повний текст джерела

Анотація:

ABSTRACT Background The breakfast meal often results in the largest postprandial hyperglycemic excursion in people with type 2 diabetes. Objective Our purpose was to investigate whether restricting carbohydrates at breakfast would be a simple and feasible strategy to reduce daily exposure to postprandial hyperglycemia. Design Adults with physician-diagnosed type 2 diabetes [n = 23; mean ± SD age: 59 ± 11 y; glycated hemoglobin: 6.7% ± 0.6%; body mass index (kg/m2): 31 ± 7] completed two 24-h isocaloric intervention periods in a random order. Participants consumed one of the following breakfasts: 1) a very-low-carbohydrate high-fat breakfast (LCBF; <10% of energy from carbohydrate, 85% of energy from fat, 15% of energy from protein) or 2) a breakfast with dietary guidelines–recommended nutrient profile (GLBF; 55% of energy from carbohydrate, 30% of energy from fat, 15% of energy from protein), with the same lunch and dinner provided. Continuous glucose monitoring was used to assess postprandial glucose responses over 24 h, and visual analog scales were used to assess ratings of hunger and fullness. Results The LCBF significantly reduced postprandial hyperglycemia after breakfast (P < 0.01) and did not adversely affect glycemia after lunch or dinner. As such, overall postprandial hyperglycemia (24-h incremental area under the glucose curve) and glycemic variability (mean amplitude of glycemic excursions) were reduced with the LCBF (24-h incremental area under the glucose curve: −173 ± 361 mmol/L; P = 0.03; mean amplitude of glycemic excursions: −0.4 ± 0.8 mmol/L · 24 h; P = 0.03) compared with the GLBF. Premeal hunger was lower before dinner with the LCBF than with the GLBF (P-interaction = 0.03). Conclusions A very-low-carbohydrate high-fat breakfast lowers postbreakfast glucose excursions. The effects of this simple strategy appear to be sufficient to lower overall exposure to postprandial hyperglycemia and improve glycemic variability. Longer-term interventions are warranted. This trial was registered at clinicaltrials.gov as NCT02982330.

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Abraham, Sinu Bessy, Siddharth Arunachalam, Alex Zhong, Pratik Agrawal, Ohad Cohen, and Chantal M. McMahon. "Improved Real-World Glycemic Control With Continuous Glucose Monitoring System Predictive Alerts." Journal of Diabetes Science and Technology 15, no. 1 (July 4, 2019): 91–97. http://dx.doi.org/10.1177/1932296819859334.

Повний текст джерела

Анотація:

Background: Most standalone real-time continuous glucose monitoring (RT-CGM) systems provide predictive low and high sensor glucose (SG) threshold alerts. The durations and risk of low and high SG excursions following Guardian™ Connect CGM system predictive threshold alerts were evaluated. Methods: Continuous glucose monitoring system data uploaded between January 2, 2017 and May 22, 2018 by 3133 individuals using multiple daily injections (MDIs) or continuous subcutaneous insulin infusion (CSII) therapy were deidentified and retrospectively analyzed. Glucose excursions were defined as SG values that went beyond a preset low or high SG threshold for ≥15 minutes. For a control group, thresholds were based on the median of the low SG threshold limit (70 mg/dL) and the high SG threshold limit (210 mg/dL) preset by all system users. During periods when alerts were not enabled, timestamps were identified when a predictive alert would have been triggered. The time before low horizon was 17.5 minutes and the time before high horizon was 15 minutes, of all users who enabled alerts. Excursions occurring after a low SG or high SG predictive alert were segmented into prevented, ≤20, 20-60, and >60 minutes. Results: Excursions were prevented after 59% and 39% of low and high SG predictive alerts, respectively. The risk of a low or high excursion occurring was 1.9 ( P < 0.001, 95% CI, 1.88-1.93) and 3.3 ( P < 0.001, 95% CI, 3.20-3.30) times greater, respectively, when alerts were not enabled. Conclusions: The predictive alerts of the RT-CGM system under study can help individuals living with diabetes prevent some real-world low and high SG excursions. This can be especially important for those unable to reach or maintain glycemic control with basic RT-CGM or CSII therapy.

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Haase, Krystal K., Jennifer L. Grelle, Faisal A. Khasawneh, and Chiamaka Ike. "Variability in Glycemic Control with Temperature Transitions during Therapeutic Hypothermia." Critical Care Research and Practice 2017 (2017): 1–7. http://dx.doi.org/10.1155/2017/4831480.

Повний текст джерела

Анотація:

Purpose. Patients treated with therapeutic hypothermia (TH) and continuous insulin may be at increased risk of hyperglycemia or hypoglycemia, particularly during temperature transitions. This study aimed to evaluate frequency of glucose excursions during each phase of TH and to characterize glycemic control patterns in relation to survival.Methods. Patients admitted to a tertiary care hospital for circulatory arrest and treated with both therapeutic hypothermia and protocol-based continuous insulin between January 2010 and June 2013 were included. Glucose measures, insulin, and temperatures were collected through 24 hours after rewarming.Results. 24 of 26 patients experienced glycemic excursions. Hyperglycemic excursions were more frequent during initiation versus remaining phases (36.3%, 4.3%, 2.5%, and 4.0%,p=0.002). Hypoglycemia occurred most often during rewarming (0%, 7.7%, 23.1%, and 3.8%,p=0.02). Patients who experienced hypoglycemia had higher insulin doses prior to rewarming (16.2 versus 2.1 units/hr,p=0.03). Glucose variation was highest during hypothermia and trended higher in nonsurvivors compared to survivors (13.38 versus 9.16,p=0.09). Frequency of excursions was also higher in nonsurvivors (32.3% versus 19.8%,p=0.045).Conclusions. Glycemic excursions are common and occur more often in nonsurvivors. Excursions differ by phase but risk of hypoglycemia is increased during rewarming.

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Howard, Rebecca, Juen Guo, and Kevin D. Hall. "Imprecision nutrition? Different simultaneous continuous glucose monitors provide discordant meal rankings for incremental postprandial glucose in subjects without diabetes." American Journal of Clinical Nutrition 112, no. 4 (August 7, 2020): 1114–19. http://dx.doi.org/10.1093/ajcn/nqaa198.

Повний текст джерела

Анотація:

ABSTRACT Background High postprandial glucose excursions may increase risk for disease. Individuals have widely varying glucose responses to different meals, and precision nutrition approaches often seek to personalize diets to minimize postprandial glycemic responses as measured by continuous glucose monitors (CGMs). However, it is unknown whether different CGM devices result in concordant meal rankings according to postprandial glycemic excursions. Objective We explored whether meal rankings according to postprandial glycemic excursions differ between 2 simultaneously worn CGMs. Methods We collected 27,489 simultaneous measurements from Dexcom G4 Platinum and Abbott Freestyle Libre Pro CGMs during 28 inpatient days in 16 adults without diabetes. Simultaneous glucose measurements obtained for 2 h following 760 ad libitum meals were used to compare within-subject meal rankings between the CGM devices according to their incremental glucose response. Results Postprandial responses to ad libitum meals were highly variable, with the Abbott and Dexcom systems resulting in within-subject incremental mean ± SD glucose CVs of 91.7 ± 1.9% and 94.2 ± 2.7%, respectively. Within-subject meal rankings for incremental glycemic responses were relatively discordant between CGMs, with a mean Kendall rank correlation coefficient of 0.43 ± 0.05. Meals in the bottom compared with those in the top half of incremental glycemic responses ranked by Abbott resulted in 50 ± 10% (P = 0.0002) less glycemic reduction as measured by Dexcom, and vice versa. The missing glycemic reduction by eating meals ranked according to the discordant CGM was inversely correlated with each subject's Kendall rank correlation coefficient (r = −0.95; P < 0.0001). Conclusions Precision nutrition approaches that use CGMs to personalize meal recommendations for minimizing glycemic excursions may be premature given the discordance of within-subject meal rankings between simultaneous CGM devices. More research is needed to clarify the source of this imprecision. This trial was registered at clinicaltrials.gov as NCT03407053.

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Wajchenberg, Bernardo Léo. "Postprandial glycemia and cardiovascular disease in diabetes mellitus." Arquivos Brasileiros de Endocrinologia & Metabologia 51, no. 2 (March 2007): 212–21. http://dx.doi.org/10.1590/s0004-27302007000200010.

Повний текст джерела

Анотація:

This article reviews the role of fasting and postprandial glycemia to the overall glycemic control of patients with type 2 diabetes and glucose intolerance, as well as their causal relationship upon micro and macrovascular complications. Recent studies have suggested that a third component of the glucose triad, the postprandial glucose excursions, might have a role in the overall glycemic load and might also reflect glycemic control. Epidemiological and intervention studies are presented in the article, supporting the conclusion that postprandial hyperglycemia in impaired glucose tolerance and diabetic subjects is a more powerful marker of cardiovascular disease risk than fasting hyperglycemia, then the treatment directed at specifically lowering postprandial glucose is crucial, as underlined by the American Diabetes Association.

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Gillen, Jenna B., Stephanie Estafanos, and Alexa Govette. "Exercise-nutrient interactions for improved postprandial glycemic control and insulin sensitivity." Applied Physiology, Nutrition, and Metabolism 46, no. 8 (August 2021): 856–65. http://dx.doi.org/10.1139/apnm-2021-0168.

Повний текст джерела

Анотація:

Type 2 diabetes (T2D) is a rapidly growing yet largely preventable chronic disease. Exaggerated increases in blood glucose concentration following meals is a primary contributor to many long-term complications of the disease that decrease quality of life and reduce lifespan. Adverse health consequences also manifest years prior to the development of T2D due to underlying insulin resistance and exaggerated postprandial concentrations of the glucose-lowering hormone insulin. Postprandial hyperglycemic and hyperinsulinemic excursions can be improved by exercise, which contributes to the well-established benefits of physical activity for the prevention and treatment of T2D. The aim of this review is to describe the postprandial dysmetabolism that occurs in individuals at risk for and with T2D, and highlight how acute and chronic exercise can lower postprandial glucose and insulin excursions. In addition to describing the effects of traditional moderate-intensity continuous exercise on glycemic control, we highlight other forms of activity including low-intensity walking, high-intensity interval exercise, and resistance training. In an effort to improve knowledge translation and implementation of exercise for maximal glycemic benefits, we also describe how timing of exercise around meals and post-exercise nutrition can modify acute and chronic effects of exercise on glycemic control and insulin sensitivity. Novelty: Exaggerated postprandial blood glucose and insulin excursions are associated with disease risk. Both a single session and repeated sessions of exercise improve postprandial glycemic control in individuals with and without T2D. The glycemic benefits of exercise can be enhanced by considering the timing and macronutrient composition of meals around exercise.

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Jakubowicz, Daniela, Julio Wainstein, Shani Tsameret, and Zohar Landau. "Role of High Energy Breakfast “Big Breakfast Diet” in Clock Gene Regulation of Postprandial Hyperglycemia and Weight Loss in Type 2 Diabetes." Nutrients 13, no. 5 (May 5, 2021): 1558. http://dx.doi.org/10.3390/nu13051558.

Повний текст джерела

Анотація:

Postprandial hyperglycemia (PPHG) is strongly linked with the future development of cardiovascular complications in type 2 diabetes (T2D). Hence, reducing postprandial glycemic excursions is essential in T2D treatment to slow progressive deficiency of β-cell function and prevent cardiovascular complications. Most of the metabolic processes involved in PPHG, i.e., β-cell secretory function, GLP-1 secretion, insulin sensitivity, muscular glucose uptake, and hepatic glucose production, are controlled by the circadian clock and display daily oscillation. Consequently, postprandial glycemia displays diurnal variation with a higher glycemic response after meals with the same carbohydrate content, consumed at dusk compared to the morning. T2D and meal timing schedule not synchronized with the circadian clock (i.e., skipping breakfast) are associated with disrupted clock gene expression and is linked to PPHG. In contrast, greater intake in the morning (i.e., high energy breakfast) than in the evening has a resetting effect on clock gene oscillations and beneficial effects on weight loss, appetite, and reduction of PPHG, independently of total energy intake. Therefore, resetting clock gene expression through a diet intervention consisting of meal timing aligned to the circadian clock, i.e., shifting most calories and carbohydrates to the early hours of the day, is a promising therapeutic approach to improve PPHG in T2D. This review will focus on recent studies, showing how a high-energy breakfast diet (Bdiet) has resetting and synchronizing actions on circadian clock genes expression, improving glucose metabolism, postprandial glycemic excursions along with weight loss in T2D.

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Moreira, Fernanda Duarte, Caio Eduardo Gonçalves Reis, Alexis Fonseca Welker, and Andrea Donatti Gallassi. "Acute Flaxseed Intake Reduces Postprandial Glycemia in Subjects with Type 2 Diabetes: A Randomized Crossover Clinical Trial." Nutrients 14, no. 18 (September 10, 2022): 3736. http://dx.doi.org/10.3390/nu14183736.

Повний текст джерела

Анотація:

Background: Postprandial glycemic excursions are associated with impairment control of diabetes mellitus. Long-term consumption of flaxseed can lower blood glucose levels; however, its effects on the postprandial glycemic response remain unknown. Therefore, this study aimed to evaluate the acute effects of raw flaxseed consumption on the 2 h postprandial glycemic curve in men with type 2 diabetes mellitus (T2DM). Methods: This was a randomized crossover clinical trial. Nineteen men with T2DM were randomly assigned a standardized breakfast without (control) or with a previous intake of 15 g of ground raw golden flaxseed (flax). Glycemia was measured at fasting and postprandial at 15, 30, 45, 60, 90, and 120 min. Palatability markers (visual appeal, smell, and pleasantness of taste) and taste intensity (sweetness, saltiness, bitterness, sourness, and creaminess) were evaluated. Results: The peak glucose rise and the 2 h AUC glycemic response reduced in the flax group by 17% (p = 0.001) and 24% (p < 0.001), respectively. The glucose peak time, palatability, and taste parameters did not differ between the two groups. Conclusions: Ingestion of 15 g of ground raw golden flaxseed before breakfast decreases the 2 h postprandial glycemic response in men with T2DM.

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Swaminathan S, Abirami MJ, and Oviya Senthilraj. "Diagnostic Usefulness of 1, 5 Anhyroglucitol in Diabetes Mellitus: A Review." International Journal of Research in Pharmaceutical Sciences 10, no. 2 (April 15, 2019): 935–42. http://dx.doi.org/10.26452/ijrps.v10i2.278.

Повний текст джерела

Анотація:

1,5 AG is a six carbon chain monosaccharide and is one of the major polyols present in humans. The approximate normal levels of 1,5AG are about 20 -40 µg/mL. The main source of 1,5AG is diet containing carbohydrates, and this 1,5AG undergoes similar metabolic pathways like other saccharides and is distributed in all organs and tissues. Once DM is confirmed and treatment initiated, it is important to monitor glycemic control at regular intervals of time. While HbA1c has been used as a gold standard to monitor diabetic control during the preceding 2-3 months, GA and FA were used to monitor short time glycemic control. But none of the above three serves to monitor glycemic excursion after meals. 1,5AG has been emerging as an alternative short-term diabetic control monitoring marker to assess short term glycemic excursions. 1,5 AG has also been found to be useful to monitor CVD, CLD patients as well in the clinical usefulness of subtypes of DM. This review article gives a condensed version of research findings during the last two decades and will be very useful for future researchers to expand the clinical usefulness of 1,5AG in other areas of human health.

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Angadi, Siddhartha, Jessica Rodriguez, Nathan Weltman, Arthur Weltman, James Patrie, and Glenn A. Gaesser. "Effects Of Glycemic Index And Dietary Fiber On Postprandial Insulin and Glycemic Excursions." Medicine & Science in Sports & Exercise 42 (May 2010): 764. http://dx.doi.org/10.1249/01.mss.0000386216.44103.79.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Scappaticcio, Lorenzo, Maria Ida Maiorino, Elisabetta Ida Maiorino, Ofelia Casciano, Paolo Cirillo, Mariangela Caputo, Katherine Esposito, Dario Giugliano, and Giuseppe Bellastella. "Serum but not salivary cortisol levels are influenced by daily glycemic oscillations in type 2 diabetes." Problems of Endocrinology 62, no. 5 (September 22, 2016): 17–18. http://dx.doi.org/10.14341/probl201662517-18.

Повний текст джерела

Анотація:

Diurnal salivary and plasma cortisol variations are considered valid expression of circadian cortisol rhythmicity. The aim of this study was to assess the reliability of salivary and plasma cortisol evaluating if glycemia and glycemic oscillations may interfere with their concentration.Methods: Forty-seven type 2 diabetic patients and 31 controls were studied for glycemic profile and diurnal salivary and plasma cortisol variations on two contemporary samples taken at 08:00 a.m. and 11:00 p.m (Late Night, LN). Glucose variability was evaluated in diabetic patients by considering the standard deviation of blood glucose (BGSD) readings, by calculating the mean amplitude of glycemic excursions (MAGEs) and continuous overlapping net glycemic action (CONGA).Results: A significant correlation between LN serum cortisol and morning fasting glycemia (r = 0.78; p = 0.004) was observed in T2DM group but not in the control group (r = 0.09; p = 0.74). While LN serum cortisol significantly correlated with CONGA in diabetic patients (r = 0.50; p < 0.001), LN salivary cortisol did not correlate with any indices of glucose variability. Moreover, a highly significant correlation between LN salivary and LN serum cortisol concentrations was found in control group (r = 0.80; p < 0.001) but not in diabetic patients (r = 0.07; p = 0.62) .Conclusions: This study shows for the first time that late night salivary cortisol may give more information than late night plasma cortisol on the dynamic of adrenal function of type 2 diabetic patients, as it is not significantly influenced by glycemic variations.

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Chernikova, N. A., L. L. Kamynina та A. S. Ametov. "The сardiometabolic assessment of the glycemic variability in patients with diabetes mellitus: the role of the glucocardiomonitoring". Kardiologiia 60, № 5 (4 травня 2020): 100–106. http://dx.doi.org/10.18087/cardio.2020.5.n902.

Повний текст джерела

Анотація:

Aim To study quantitatively the two-way relationship between parameters of glycemic variability and development of cardiovascular events in patients with type 2 diabetes mellitus (DM) on chronic sulfonylurea (SM) therapy by synchronous, professional glucose and cardiac monitoring.Material and methods The study included 421 patients with type 2 DM on SM therapy. A 5-day synchronous glucose and cardiac monitoring was performed for these patients in a retrospective mode using an iPro2 (Medtronic, USA) continuous glycemia monitoring (CGM) system and Holter monitoring. Glycemic endpoints (CGM-parameters of glycemia variability and integral indexes) and cardiological endpoints (ventricular rhythm disorders (VRD), ST segment depression (dST), and corrected QT interval (QTc)) were evaluated.Results Clear correlations were found between the ST segment depression and the increase in TIR-HYPO index and the length of QTc. The strongest correlation was observed for VRD and the increase in TIR-HYPO. Moderate correlations were observed between VRD and the decrease in TIR-NORMO and between increased variabilities of glycemia (increases in SD and number of glycemia excursions >4 mmol/l/h) and integral indexes (mean CGM-level of glycemia and HbA1c). Elongation of the QTc interval was associated with increased TIR-HYPO, decrease in maximum glycemia, and development of dST.Conclusion The glucose and cardiac monitoring confirmed the close interrelation between the quality of glycemic control and cardiovascular disorders and should be recommended for a wider use in real-life clinical practice for determining the cardiometabolic status of patients and personalization of hypoglycemic therapy.

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Parkin, Christopher G., and Jaime A. Davidson. "Value of Self-Monitoring Blood Glucose Pattern Analysis in Improving Diabetes Outcomes." Journal of Diabetes Science and Technology 3, no. 3 (May 2009): 500–508. http://dx.doi.org/10.1177/193229680900300314.

Повний текст джерела

Анотація:

Self-monitoring of blood glucose (SMBG) is an important adjunct to hemoglobin A1c (HbA1c) testing. This action can distinguish between fasting, preprandial, and postprandial hyperglycemia; detect glycemic excursions; identify and monitor resolution of hypoglycemia; and provide immediate feedback to patients about the effect of food choices, activity, and medication on glycemic control. Pattern analysis is a systematic approach to identifying glycemic patterns within SMBG data and then taking appropriate action based upon those results. The use of pattern analysis involves: (1) establishing pre- and postprandial glucose targets; (2) obtaining data on glucose levels, carbohydrate intake, medication administration (type, dosages, timing), activity levels and physical/emotional stress; (3) analyzing data to identify patterns of glycemic excursions, assessing any influential factors, and implementing appropriate action(s); and (4) performing ongoing SMBG to assess the impact of any therapeutic changes made. Computer-based and paper-based data collection and management tools can be developed to perform pattern analysis for identifying patterns in SMBG data. This approach to interpreting SMBG data facilitates rational therapeutic adjustments in response to this information. Pattern analysis of SMBG data can be of equal or greater value than measurement of HbA1c levels.

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Galindo, Rodolfo J., Roy W. Beck, Maria F. Scioscia, Guillermo E. Umpierrez, and Katherine R. Tuttle. "Glycemic Monitoring and Management in Advanced Chronic Kidney Disease." Endocrine Reviews 41, no. 5 (May 26, 2020): 756–74. http://dx.doi.org/10.1210/endrev/bnaa017.

Повний текст джерела

Анотація:

Abstract Glucose and insulin metabolism in patients with diabetes are profoundly altered by advanced chronic kidney disease (CKD). Risk of hypoglycemia is increased by failure of kidney gluconeogenesis, impaired insulin clearance by the kidney, defective insulin degradation due to uremia, increased erythrocyte glucose uptake during hemodialysis, impaired counterregulatory hormone responses (cortisol, growth hormone), nutritional deprivation, and variability of exposure to oral antihyperglycemic agents and exogenous insulin. Patients with end-stage kidney disease frequently experience wide glycemic excursions, with common occurrences of both hypoglycemia and hyperglycemia. Assessment of glycemia by glycated hemoglobin (HbA1c) is hampered by a variety of CKD-associated conditions that can bias the measure either to the low or high range. Alternative glycemic biomarkers, such as glycated albumin or fructosamine, are not fully validated. Therefore, HbA1c remains the preferred glycemic biomarker despite its limitations. Based on observational data for associations with mortality and risks of hypoglycemia with intensive glycemic control regimens in advanced CKD, an HbA1c range of 7% to 8% appears to be the most favorable. Emerging data on the use of continuous glucose monitoring in this population suggest promise for more precise monitoring and treatment adjustments to permit fine-tuning of glycemic management in patients with diabetes and advanced CKD.

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Maia, Frederico F. R., and Levimar R. Araújo. "Efficacy of continuous glucose monitoring system to detect unrecognized hypoglycemia in children and adolescents with type 1 diabetes." Arquivos Brasileiros de Endocrinologia & Metabologia 49, no. 4 (August 2005): 569–74. http://dx.doi.org/10.1590/s0004-27302005000400016.

Повний текст джерела

Анотація:

This retrospective study assessed 17 DM1 pediatric patients (15.76 ± 4.5 years) submitted to 72h continuous glucose monitoring system (CGMS) (Medtronic, CA). The aim of this study was to evaluate the accuracy of CGMS in children and adolescents with type 1 diabetes mellitus (DM1) and the efficacy of this method to detect unrecognized hypoglycemia in this population. It were analyzed capillary glycemia (CG) and CGMS sensor’s value; glycemic excursions; postprandial hyperglycemia; unrecognized hypoglycemia; complications and therapeutic management after CGMS. A1c levels were measured at the start and after 3 months of the study. Correlation coefficient during hypo, hyper, and normoglycemia and sensitivity/specificity was determined. The mean CG values were 213.8 ± 63.4mg/dl vs. 209.7 ± 52.5mg/dl by sensor, with statistical significance by Pearson’s correlation (p< 0.001). There was no difference between CGMS and CG value in order to detect glycemic excursions (p= 0.32). The postprandial hyperglycemia and unrecognized hypoglycemia was detected in 66.7% and 56.2% of this patients, respectively. The correlation coefficient during hypoglycemia presented no statistical significance by Pearson’s correlation (p= 0.29) vs. during hyperglycemia (p= 0.001). The CGMS sensor presented low sensitivity (63.3%) to detect hypoglycemia. This data showed important decreased level of A1c in this population 3 months after CGMS with statistical significance (p= 0.03). The CGMS showed to be a very safe method, well tolerated, with high accuracy in glycemic values and low complications rate. This results suggest that CGMS is a good method to identify postprandial hyperglycemia, to improve metabolic changes in therapeutics with significant impact in A1c of diabetic pediatric patients. This data confirmed the low sensitivity of CGMS to detect unrecognized hypoglycemia in pediatric DM1 patients.

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Dungan, Kathleen M. "1,5-anhydroglucitol (GlycoMark™) as a marker of short-term glycemic control and glycemic excursions." Expert Review of Molecular Diagnostics 8, no. 1 (January 2008): 9–19. http://dx.doi.org/10.1586/14737159.8.1.9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Montt-Blanchard, Denise, Raimundo Sánchez, Karen Dubois-Camacho, Jaime Leppe, and María Teresa Onetto. "Hypoglycemia and glycemic variability of people with type 1 diabetes with lower and higher physical activity loads in free-living conditions using continuous subcutaneous insulin infusion with predictive low-glucose suspend system." BMJ Open Diabetes Research & Care 11, no. 2 (March 2023): e003082. http://dx.doi.org/10.1136/bmjdrc-2022-003082.

Повний текст джерела

Анотація:

IntroductionMaintaining glycemic control during and after physical activity (PA) is a major challenge in type 1 diabetes (T1D). This study compared the glycemic variability and exercise-related diabetic management strategies of adults with T1D achieving higher and lower PA loads in nighttime–daytime and active– sedentary behavior hours in free-living conditions.Research design and methodsActive adults (n=28) with T1D (ages: 35±10 years; diabetes duration: 21±11 years; body mass index: 24.8±3.4 kg/m2; glycated hemoglobin A1c: 6.9±0.6%) on continuous subcutaneous insulin delivery system with predictive low glucose suspend system and glucose monitoring, performed different types, duration and intensity of PA under free-living conditions, tracked by accelerometer over 14 days. Participants were equally divided into lower load (LL) and higher load (HL) by median of daily counts per minute (61122). Glycemic variability was studied monitoring predefined time in glycemic ranges (time in range (TIR), time above range (TAR) and time below range (TBR)), coefficient of variation (CV) and mean amplitude of glycemic excursions (MAGE). Parameters were studied in defined hours timeframes (nighttime–daytime and active–sedentary behavior). Self-reported diabetes management strategies were analysed during and post-PA.ResultsHigher glycemic variability (CV) was observed in sedentary hours compared with active hours in the LL group (p≤0.05). HL group showed an increment in glycemic variability (MAGE) during nighttime versus daytime (p≤0.05). There were no differences in TIR and TAR across all timeframes between HL and LL groups. The HL group had significantly more TBR during night hours than the LL group (p≤0.05). Both groups showed TBR above recommended values. All participants used fewer post-PA management strategies than during PA (p≤0.05).ConclusionActive people with T1D are able to maintain glycemic variability, TIR and TAR within recommended values regardless of PA loads. However, the high prevalence of TBR and the less use of post-PA management strategies highlights the potential need to increase awareness on actions to avoid glycemic excursions and hypoglycemia after exercise completion.

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Dupre, J., M. T. Behme, I. M. Hramiak, P. McFarlane, M. P. Williamson, P. Zabel, and T. J. McDonald. "Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM." Diabetes 44, no. 6 (June 1, 1995): 626–30. http://dx.doi.org/10.2337/diab.44.6.626.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Dupré, John, Margaret T. Behme, and Thomas J. McDonald. "Exendin-4 Normalized Postcibal Glycemic Excursions in Type 1 Diabetes." Journal of Clinical Endocrinology & Metabolism 89, no. 7 (July 2004): 3469–73. http://dx.doi.org/10.1210/jc.2003-032001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Dupre, J., M. T. Behme, I. M. Hramiak, P. McFarlane, M. P. Williamson, P. Zabel, and T. J. McDonald. "Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM." Diabetes 44, no. 6 (June 1, 1995): 626–30. http://dx.doi.org/10.2337/diabetes.44.6.626.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Varanasi, Ajay, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, and Paresh Dandona. "Liraglutide as additional treatment for type 1 diabetes." European Journal of Endocrinology 165, no. 1 (July 2011): 77–84. http://dx.doi.org/10.1530/eje-11-0330.

Повний текст джерела

Анотація:

ObjectiveTo determine whether the addition of liraglutide to insulin to treat patients with type 1 diabetes leads to an improvement in glycemic control and diminish glycemic variability.Subjects and methodsIn this study, 14 patients with well-controlled type 1 diabetes on continuous glucose monitoring and intensive insulin therapy were treated with liraglutide for 1 week. Of the 14 patients, eight continued therapy for 24 weeks.ResultsIn all the 14 patients, mean fasting and mean weekly glucose concentrations significantly decreased after 1 week from 130±10 to 110±8 mg/dl (P<0.01) and from 137.5±20 to 115±12 mg/dl (P<0.01) respectively. Glycemic excursions significantly improved at 1 week. The mean s.d. of glucose concentrations decreased from 56±10 to 26±6 mg/dl (P<0.01) and the coefficient of variation decreased from 39.6±10 to 22.6±7 (P<0.01). There was a concomitant fall in the basal insulin from 24.5±6 to 16.5±6 units (P<0.01) and bolus insulin from 22.5±4 to 15.5±4 units (P<0.01).In patients who continued therapy with liraglutide for 24 weeks, mean fasting, mean weekly glucose concentrations, glycemic excursions, and basal and bolus insulin dose also significantly decreased (P<0.01). HbA1c decreased significantly at 24 weeks from 6.5 to 6.1% (P=0.02), as did the body weight by 4.5±1.5 kg (P=0.02).ConclusionLiraglutide treatment provides an additional strategy for improving glycemic control in type 1 diabetes. It also leads to weight loss.

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Barouti, Afroditi Alexandra, Anneli Björklund, Sergiu Bogdan Catrina, Kerstin Brismar, and Neda Rajamand Ekberg. "Effect of Isocaloric Meals on Postprandial Glycemic and Metabolic Markers in Type 1 Diabetes—A Randomized Crossover Trial." Nutrients 15, no. 14 (July 10, 2023): 3092. http://dx.doi.org/10.3390/nu15143092.

Повний текст джерела

Анотація:

The aim of this study was to assess the effect of four isocaloric meals with different macronutrient compositions on postprandial blood glucose, lipids, and glucagon in adults with type 1 diabetes (T1D). Seventeen subjects tested four isocaloric meals in a randomized crossover design. The meal compositions were as follows: high-carbohydrate (HC); high-carbohydrate with extra fiber (HC-fiber); low-carbohydrate high-protein (HP); and low-carbohydrate high-fat (HF). Blood glucose and lipid measurements were collected up to 4 h and glucagon up to 3 h postprandially. Mean postprandial glucose excursions were lower after the HP compared to the HC (p = 0.036) and HC-fiber meals (p = 0.002). There were no differences in mean glucose excursions after the HF meal compared to the HC and HP meals. The HF meal resulted in higher triglyceride excursions compared to the HP meal (p < 0.001) but not compared to the HC or HC-fiber meals. Glucagon excursions were higher at 180 min after the HP meal compared to the HC and HF meals. In conclusion, the low-carbohydrate HP meal showed the most favorable glycemic and metabolic effects during a 4 h postprandial period in subjects with T1D.

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Kovatchev, Boris. "Glycemic Variability: Risk Factors, Assessment, and Control." Journal of Diabetes Science and Technology 13, no. 4 (January 29, 2019): 627–35. http://dx.doi.org/10.1177/1932296819826111.

Повний текст джерела

Анотація:

Glycemic variability (GV) a well-established risk factor for hypoglycemia and a suspected risk factor for diabetes complications. GV is also a marker of the instability of a person’s metabolic system, expressed as frequent high and low glucose excursions and overall volatile glycemic control. In this review, the author discusses topics related to the assessment, quantification, and optimal control of diabetes, including (1) the notion that optimal control of diabetes, that is, lowering of HbA1c—the commonly accepted gold-standard outcome—can be achieved only if accompanied by simultaneous reduction of GV; (2) assessment and visualization of the two principal dimensions of GV, amplitude and time, which is now possible via continuous glucose monitoring (CGM) and various metrics quantifying GV and the risks associated with hypo- and hyperglycemic excursions; and (3) the evolution of diabetes science and technology beyond quantifying GV and into the realm of GV control via pharmacological agents, for example, GLP-1 receptor agonists and DPP-4 inhibitors, which have pronounced variability-reducing effect, or real-time automated closed-loop systems commonly referred to as the “artificial pancreas.” The author concludes that CGM allows close tracking over time, and therefore precise quantification, of glycemic variability in diabetes. The next step—optimal control of glucose fluctuations—is also taken by medications with pronounced GV-lowering effect primarily in type 2 diabetes, and by automated insulin delivery in type 1 diabetes. Contemporary CGM-based artificial pancreas systems use specific GV representations as input signals, and thus their main objective is to minimize GV and, from there, optimize glycemic control.

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Shivaprasad, Channabasappa, Yalamanchi Aiswarya, Shah Kejal, Atluri Sridevi, Biswas Anupam, Barure Ramdas, Kolla Gautham, and Premchander Aarudhra. "Comparison of CGM-Derived Measures of Glycemic Variability Between Pancreatogenic Diabetes and Type 2 Diabetes Mellitus." Journal of Diabetes Science and Technology 15, no. 1 (July 7, 2019): 134–40. http://dx.doi.org/10.1177/1932296819860133.

Повний текст джерела

Анотація:

Background: To compare glycemic variability (GV) indices between patients with fibrocalculous pancreatic diabetes (FCPD) and type 2 diabetes mellitus (T2D) using continuous glucose monitoring (CGM). Methods: We measured GV indices using CGM (iPro™2 Professional CGM, Medtronic, USA) data in 61 patients each with FCPD and T2D who were matched for glycated hemoglobin A1c (HbA1c) and duration of diabetes. GlyCulator2 software was used to estimate the CGM-derived measures of GV (SD, mean amplitude of glycemic excursion [MAGE], continuous overall net glycemic action [CONGA], absolute means of daily differences [MODD], M value, and coefficient of variance [%CV]), hypoglycemia (time spent below 70 mg/dL, AUC below 70 mg/dL, glycemic risk assessment diabetes equation hypoglycemia, Low Blood Glucose Index), and hyperglycemia (time spent above 180 mg/dL at night [TSA > 180], AUC above 180 mg/dL [AUC > 180], glycemic risk assessment diabetes equation hyperglycemia, High Blood Glucose Index [HBGI], and J index). The correlation of GV indices with HbA1c, duration of diabetes, and demographic and biochemical parameters were also assessed. Results: All the CGM-derived measures of GV (SD, MAGE, CONGA, MODD, and %CV), except M value, were significantly higher in the FCPD group than in the T2D group ( P < 0.05). Measures of hyperglycemia (TSA >180, AUC >180, HBGI, and J index) were significantly higher in the FCPD group than in the T2D group ( P < 0.05). The measures of hypoglycemia were not significantly different between the two groups. All the hyperglycemia indices showed a positive correlation with HbA1c in both groups. Conclusions: FCPD is associated with higher GV than is T2D. The findings of higher postprandial glycemic excursions in patients with FCPD could have potential therapeutic implications.

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Disotuar, Maria M., Diao Chen, Nai-Pin Lin, and Danny Hung-Chieh Chou. "Glucose-Responsive Insulin Through Bioconjugation Approaches." Journal of Diabetes Science and Technology 14, no. 2 (June 19, 2019): 198–203. http://dx.doi.org/10.1177/1932296819854105.

Повний текст джерела

Анотація:

Although insulin analogs have markedly improved glycemic control for people with diabetes, glycemic excursions still cause major health problems and complications. In particular, the narrow therapeutic window of current insulin therapy makes it extremely difficult to maintain normoglycemia without risking severe hypoglycemia. Currently, there are no FDA-approved insulin therapeutics whose bioactivity is regulated by blood glucose levels. This review discusses recent progress on developing glucose-responsive insulin (GRI) bioconjugates without the need of exogenous matrices. Through this approach, tremendous efforts have been made over the years to demonstrate the promise of better glycemic control and reduced risk of hypoglycemia. Last, we discuss future directions of GRI development with a goal to maximize the glucose responsiveness.

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Liu, Bing-li, Guo-ping Yin, Feng-fei Li, Yun Hu, Jin-dan Wu, Mao-yuan Chen, Lei Ye, Xiao-fei Su, and Jian-hua Ma. "Comparison of Efficacy and Safety of Lispro and Aspart Evaluated by Continuous Glucose Monitoring System in Patients with Newly Diagnosed Type 2 Diabetes." International Journal of Endocrinology 2018 (2018): 1–7. http://dx.doi.org/10.1155/2018/2087960.

Повний текст джерела

Анотація:

Objective. To compare the effect of the rapid-acting insulin analogues (RAIAs) aspart (NovoRapid) and lispro (Prandilin) on glycemic variations by continuous glucose monitoring system (CGMS) in patients within newly diagnosed type 2 diabetes mellitus (T2DM) receiving continuous subcutaneous insulin infusion (CSII) and metformin intensive therapy. Methods. This is a single-blind randomized controlled trial. A total of 110 patients with newly diagnosed T2DM and with hemoglobin A1c (HbA1c%) above 9% was hospitalized and randomly divided into two groups: group Asp (NovoRapid group) and group Lis (Prandilin group). They all received CSII and metformin therapy. Treatments were maintained for 2-3 weeks after the glycaemic target was reached. C-peptide and insulin and fructosamine were determined. CGMS was continuously applied for 4 days after reaching the glycemic target. Results. There were no significant differences in daily dosages of insulin, fasting plasma C-P and 2 h postprandial C-P and insulin, and fructosamine at the baseline and endpoint between the groups Asp and Lis. No significant differences were seen in the 24 h mean amplitude of glycemic excursions (MAGE), 24 h mean blood glucose (MBG), the standard deviation of the MBG (SDBG), fasting blood glucose, number of glycemic excursion (NGE), and the incidence of hypoglycemia between the two groups. Similarly, no significant differences were found in areas under the curve (AUC) of glucose above 10.0 mmol/L or the decremental area over the curve (AOC) of glucose below 3.9 mmol/L between the two groups. Conclusions. Lispro and aspart had the similar ability to control the glycemic variations in patients with newly diagnosed T2DM. This study was registered with ClinicalTrials.gov, number ChiCTR-IPR-17010338.

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Tartaglione, Linda, Enrico di Stasio, Angelo Sirico, Mauro Di Leo, Salvatore Caputo, Alessandro Rizzi, Agnese Caneschi, Sara De Carolis, Dario Pitocco, and Antonio Lanzone. "Continuous Glucose Monitoring in Women with Normal OGTT in Pregnancy." Journal of Diabetes Research 2021 (August 23, 2021): 1–8. http://dx.doi.org/10.1155/2021/9987646.

Повний текст джерела

Анотація:

Continuous glucose monitoring (CGM) might be an effective tool to improve glycemic control in gestational diabetes mellitus (GDM). Few data are available about its utilization as a diagnostic tool to find potential alterations of glycemia in subjects with normal oral glucose tolerance test (OGTT). In this preliminary prospective real-life observational study, we aimed to analyze the glycemic pattern in normal and gestational diabetes mellitus (GDM) women by continuous glucose monitoring (CGM) in order to detect potential differences between the two groups and glycemic alterations despite a normal OGTT. After the screening for GDM, subjects were connected to a CGM system for seven consecutive days. The areas under the curve of the first 60 minutes after each meal and 60 minutes before breakfast were analyzed. Women with normal OGTT that during CGM showed impaired glycemic values (more than 95 fasting or more than 140 one hour after meals or more than 120 two hours after meals) performed one week of self-monitoring of blood glucose (SMBG). After OGTT, 53 women considered normal and 46 affected by GDM were included. CGM parameters did not show any differences between the two groups with impaired glycemic excursions found in both groups. After CGM period, 33 women with normal OGTT showed abnormal glycemic patterns. These 33 women then performed one week of SMBG. After evaluation of one week of SMBG, 21 required diet therapy and 12 required insulin treatment and were followed until the delivery. An increase in gestational weight gain was observed in normal women with normal OGTT but this was not significant. No significant data were found regarding neonatal outcomes in the two groups of women. In conclusion, CGM use in pregnancy might help to detect glycemic fluctuations in women with normal OGTT, improving their treatment and outcomes.

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Akoko, Sokiprim, and Amarachi Queen Nwaogwugwu. "Effect of Vegetables with Carbohydrate Meal on Glucose Excursions and Glycemic Control among Healthy Adults in Port Harcourt." Saudi Journal of Biomedical Research 8, no. 07 (July 15, 2023): 100–106. http://dx.doi.org/10.36348/sjbr.2023.v08i07.003.

Повний текст джерела

Анотація:

Aim: This study aimed to investigate the impact of different meal compositions on glycemic control in healthy adults in the University of Port Harcourt by examining the order and combination of carbohydrate and vegetable consumption. Method: A randomized crossover trial was conducted with 30 male and female participants. Three groups were formed, each consuming meals consisting of carbohydrates and vegetables in different sequences. Continuous glucose monitoring and postprandial glucose tests were employed to assess blood glucose levels. The glycemic index (GI) of the meals was also determined. Results: Participants who consumed vegetables before carbohydrates exhibited significantly lower mean glucose levels compared to the other groups. The Vegetable before Carbohydrate group demonstrated a lower overall glycemic response, as indicated by the lower GI values at various time intervals. Conclusion: The findings suggest that consuming vegetables before carbohydrates can lead to better glycemic control in healthy adults. The order of food consumption plays a role in regulating postprandial blood glucose levels. Including vegetables, which have a low glycemic index, in carbohydrate meals can mitigate rapid spikes in blood glucose levels.

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Nusca, Annunziata, Angelo Lauria Pantano, Rosetta Melfi, Claudio Proscia, Ernesto Maddaloni, Rocco Contuzzi, Fabio Mangiacapra, et al. "Glycemic Variability Assessed by Continuous Glucose Monitoring and Short-Term Outcome in Diabetic Patients Undergoing Percutaneous Coronary Intervention: An Observational Pilot Study." Journal of Diabetes Research 2015 (2015): 1–11. http://dx.doi.org/10.1155/2015/250201.

Повний текст джерела

Анотація:

Poor glycemic control is associated with unfavorable outcome in patients undergoing percutaneous coronary intervention (PCI), irrespective of diabetes mellitus. However a complete assessment of glycemic status may not be fully described by glycated hemoglobin or fasting blood glucose levels, whereas daily glycemic fluctuations may influence cardiovascular risk and have even more deleterious effects than sustained hyperglycemia. Thus, this paper investigated the effectiveness of a continuous glucose monitoring (CGM), registering the mean level of glycemic values but also the extent of glucose excursions during coronary revascularization, in detecting periprocedural outcome such as renal or myocardial damage, assessed by serum creatinine, neutrophil gelatinase-associated lipocalin (NGAL), and troponin I levels. High glycemic variability (GV) has been associated with worse postprocedural creatinine and NGAL variations. Moreover, GV, and predominantly hypoglycemic variations, has been observed to increase in patients with periprocedural myocardial infarction. Thus, our study investigated the usefulness of CGM in the setting of PCI where an optimal glycemic control should be achieved in order to prevent complications and improve outcome.

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Halperin, Florencia, Mary Elizabeth Patti, Megan Skow, Muhammad Bajwa, and Allison B. Goldfine. "Continuous Glucose Monitoring for Evaluation of Glycemic Excursions after Gastric Bypass." Journal of Obesity 2011 (2011): 1–7. http://dx.doi.org/10.1155/2011/869536.

Повний текст джерела

Анотація:

Background. Hyperinsulinemic hypoglycemia with neuroglycopenia is a rare complication of Roux-en-Y gastric bypass (RYGB). We hypothesized that continuous glucose monitoring (CGM) would be useful to characterize glycemic variability after RYGB.Methods. CGM and mixed meal tolerance testing (MMTT) were performed on sixteen post-RYGB subjects, ten with a history of neuroglycopenia on medical treatment and six asymptomatic controls.Results. 9 of 10 subjects with neuroglycopenia developed hypoglycemia defined by glucose <70 mg/dL on CGM, and 3 of 9 on MMTT. In asymptomatic subjects, 3 of 6 had asymptomatic hypoglycemia during CGM, and 3 of 5 on MMTT. Therefore, the sensitivity and specificity to detect clinically significant hypoglycemia was 90% and 50% for CGM and 33% and 40% for MMTT.Conclusions. Asymptomatic hypoglycemia after RYGB is more frequent than commonly recognized. For clinicians evaluating patients for postbypass neuroglycopenia, CGM may be a valuable diagnostic tool.

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Sechterberger, Marjolein K., Yoeri M. Luijf, and J. Hans DeVries. "Poor Agreement of Computerized Calculators for Mean Amplitude of Glycemic Excursions." Diabetes Technology & Therapeutics 16, no. 2 (February 2014): 72–75. http://dx.doi.org/10.1089/dia.2013.0138.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

RITHOLZ, MARILYN D., OWEN HENN, ASTRID ATAKOV-CASTILLO, LAWRENCE FISHER, and ELENA TOSCHI. "Mobile Technology for Behavioral Feedback on Glycemic Excursions—A Qualitative Study." Diabetes 67, Supplement 1 (May 2018): 931—P. http://dx.doi.org/10.2337/db18-931-p.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Tonoike, Mie, Miyako Kishimoto, Mayumi Yamamoto, Tetsu Yano, and Mitsuhiko Noda. "Continuous Glucose Monitoring in Patients with Abnormal Glucose Tolerance during Pregnancy: A Case Series." Japanese Clinical Medicine 7 (January 2016): JCM.S34825. http://dx.doi.org/10.4137/jcm.s34825.

Повний текст джерела

Анотація:

Abnormal glucose tolerance during pregnancy is associated with perinatal complications. We used continuous glucose monitoring (CGM) in pregnant women with glucose intolerance to achieve better glycemic control and to evaluate the maternal glucose fluctuations. We also used CGM in women without glucose intolerance (the control cases). Furthermore, the standard deviation (SD) and mean amplitude of glycemic excursions (MAGE) were calculated for each case. For the control cases, the glucose levels were tightly controlled within a very narrow range; however, the SD and MAGE values in pregnant women with glucose intolerance were relativity high, suggesting postprandial hyperglycemia. Our results demonstrate that pregnant women with glucose intolerance exhibited greater glucose fluctuations compared with the control cases. The use of CGM may help to improve our understanding of glycemic patterns and may have beneficial effects on perinatal glycemic control, such as the detection of postprandial hyperglycemia in pregnant women.

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Bergia, Robert E., Rosalba Giacco, Therese Hjorth, Izabela Biskup, Wenbin Zhu, Giuseppina Costabile, Marilena Vitale, Wayne W. Campbell, Rikard Landberg, and Gabriele Riccardi. "Differential Glycemic Effects of Low- versus High-Glycemic Index Mediterranean-Style Eating Patterns in Adults at Risk for Type 2 Diabetes: The MEDGI-Carb Randomized Controlled Trial." Nutrients 14, no. 3 (February 8, 2022): 706. http://dx.doi.org/10.3390/nu14030706.

Повний текст джерела

Анотація:

A Mediterranean-style healthy eating pattern (MED-HEP) supports metabolic health, but the utility of including low-glycemic index (GI) foods to minimize postprandial glucose excursions remain unclear. Therefore, we investigated the relative contribution of GI towards improvements in postprandial glycemia and glycemic variability after adopting a MED-HEP. We conducted a randomized, controlled dietary intervention, comparing high- versus low-GI diets in a multi-national (Italy, Sweden, and the United States) sample of adults at risk for type 2 diabetes. For 12 weeks, participants consumed either a low-GI or high-GI MED-HEP. We assessed postprandial plasma glucose and insulin responses to high- or low-GI meals, and daily glycemic variability via continuous glucose monitoring at baseline and post-intervention. One hundred sixty adults (86 females, 74 males; aged 55 ± 11 y, BMI 31 ± 3 kg/m2, mean ± SD) with ≥two metabolic syndrome traits completed the intervention. Postprandial insulin concentrations were greater after the high-GI versus the low-GI test meals at baseline (p = 0.004), but not post-intervention (p = 0.17). Postprandial glucose after the high-GI test meal increased post-intervention, being significantly higher than that after the low-GI test meal (35%, p < 0.001). Average daily glucose concentrations decreased in both groups post-intervention. Indices of 24-h glycemic variability were reduced in the low-GI group as compared to baseline and the high-GI intervention group. These findings suggest that low-GI foods may be an important feature within a MED-HEP.

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Alzahrani, Bader, Saad Alzahrani, Mussa H. Almalki, Souha S. Elabd, Shawana Abdulhamid Khan, Badurudeen Buhary, Naji Aljuhani, and Anwar A. Jammah. "Glycemic Variability in Type 1 Diabetes Mellitus Saudis Using Ambulatory Glucose Profile." Clinical Medicine Insights: Endocrinology and Diabetes 14 (January 2021): 117955142110137. http://dx.doi.org/10.1177/11795514211013789.

Повний текст джерела

Анотація:

Background: Glucose variability (GV) is a common and challenging clinical entity in the management of people with type 1 diabetes (T1DM). The magnitude of GV in Saudi people with T1DM was not addressed before. Therefore, we aimed to study GV in a consecutive cohort of Saudis with T1DM. Methods: We prospectively assessed interstitial glucose using FreeStyle® Libre flash glucose monitoring in people with TIDM who attended follow-up in the diabetes clinics at King Fahad Medical City between March and June 2017. Glycemia profile, standard deviation (SD), coefficient of variation (CV), mean of daily differences (MODD), and mean amplitude of glucose excursion (MAGE) were measured using the standard equations over a period of 2 weeks. Results: Fifty T1DM subjects (20 males) with mean age 20.2 ± 6.1 years and mean fortnight glucose 192 ± 42.3 mg/dl were included. The mean SD of 2-week glucose readings was 100.4 ± 36.3 mg/dl and CV was 52.1% ± 13%. Higher levels of glucose excursions were also observed. MODD and MAGE were recorded as 104.5 ± 51.7 and 189 ± 54.9 mg/dl, respectively which is 2 to 4 times higher than the international standards. Higher MODD and MAGE were observed on weekends compared to weekdays (111.3 ± 62.1 vs 98.6 ± 56.2 mg/dl and 196.4 ± 64.6 vs 181.7 ± 52.4 mg/dl, respectively; P ⩽ .001). Conclusion: Higher degree of glycemic variability was observed in this cohort of TIDM Saudis. Weekends were associated with higher glucose swings than weekdays. More studies are needed to explore these findings further.

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Du, Guoli, Wanrun Xie, Yinxia Su, Yao Ma, Xiaoming Gao, Sheng Jiang, and Huazheng Liang. "Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study." PeerJ 8 (October 2, 2020): e9905. http://dx.doi.org/10.7717/peerj.9905.

Повний текст джерела

Анотація:

Background Acarbose and repaglinide are widely used either by themselves or in combination with other medications. However, their efficacy in diabetes control has not been compared when used in combination with metformin. Methods The present study aimed to compare their effects on glycemic variability (GV) control when taken with metformin for type 2 diabetes mellitus (T2DM) inadequately controlled with metformin alone. In this retrospective cohort study, T2DM patients who were treated with either acarbose-metformin or repaglinide-metformin combination were recruited. Either acarbose 100 mg or repaglinide 2 mg triple daily was taken for the subsequent 12 weeks in combination with metformin. Demographic data, biochemical data and 7-point glycemic self-monitoring conducted with capillary blood (SMBG) data were reviewed after one week and 12 weeks. The primary outcome including glucose control and changes in GV as well as other factors affecting GV and the incidence of hypoglycemia were also analyzed. Results Of the 305 T2DM patients enrolled, data from 273 subjects, 136 in the acarbose-metformin group (M+A) and 137 in the repaglinide-metformin group (M+R) were analyzed. Both regimens improved glycemic control at 12 weeks post commencement of new medications. GV, expressed as the mean amplitude of plasma glycemic excursions (MAGE, 5.0 ± 2.6 vs. 2.8 ± 1.6 mmol/L, p < 0.001 in M+A; 5.1 ± 2.5 vs. 2.9 ± 1.3 mmol/L, p < 0.001 in M+R), standard deviation of blood glucose (SDBG, 3.6 ± 1.3 vs. 2.0 ± 0.9 mmol/L, p < 0.001 in M+A; 3.7 ± 1.3 vs. 2.4 ± 1.3 p < 0.001 in M+R), coefficient of variation of blood glucose (CVBG, (0.30 ± 0.09 vs. 0.21 ± 0.1, p < 0.001 in M+A; 0.31 ± 0.09 vs. 0.24 ± 0.12, p < 0.001 in M+R), postprandial amplitude of glycemic excursions (PPGE, 5.2 ± 2.6 vs. 2.8 ± 1.6 mmol/L, p < 0.001 in M+A; 5.3 ± 2.5 vs. 2.9 ± 1.3 mmol/L, p < 0.001 in M+R) or largest amplitude of glycemic excursions (LAGE, 9.8 ± 3.6 vs. 5.4 ± 2.4 mmol/L, p < 0.001 in M+A; 10.1 ± 3.4 vs. 6.3 ± 3.2 mmol/L, p < 0.001 in M+R) decreased significantly after the addition of acarbose or repaglinide (p < 0.05 respectively). Compared with repaglinide-metformin, acarbose-metformin was more effective in GV control at 12 weeks post commencement of new medications (p < 0.05). This study indicates that both acarbose-metformin and repaglinide-metformin combinations could effectively reduce GV and the acarbose-metformin combination seems to be more effective than the repaglinide-metformin combination. However, this conclusion should be confirmed by future large-scaled and more comprehensive studies due to the limitations of the present study.

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Wang, Jun-Sing, I.-Te Lee, Wen-Jane Lee, Shi-Dou Lin, Shih-Li Su, Shih-Te Tu, Shih-Yi Lin, and Wayne Huey-Herng Sheu. "The dawn phenomenon in type 2 diabetes: its association with glucose excursions and changes after oral glucose-lowering drugs." Therapeutic Advances in Chronic Disease 12 (January 2021): 204062232110336. http://dx.doi.org/10.1177/20406223211033674.

Повний текст джерела

Анотація:

Background: We investigated the association between glucose excursions and the dawn phenomenon, and the effects of oral-glucose lowering drugs on the dawn phenomenon in patients with type 2 diabetes (T2D). Methods: We conducted a post hoc analysis using data from a previous randomized trial. Patients with T2D on metformin monotherapy were randomized to receive add-on acarbose or glibenclamide for 16 weeks. Ambulatory continuous glucose monitoring (CGM) was conducted before randomization and at the end of the study. Using the CGM data, we assessed glucose excursions as indicated by mean amplitude of glycemic excursions (MAGE). The magnitude of the dawn phenomenon was calculated as the difference between the nocturnal nadir (0:00 to 6:00 a.m.) and prebreakfast glucose level. Results: A total of 50 patients with T2D [mean age 53.5 ± 8.2 years, mean glycated hemoglobin (HbA1c) 8.4 ± 1.2%] were analyzed. There was an independent association between MAGE and the dawn phenomenon [β coefficient 0.199, 95% confidence interval (CI) 0.074–0.325, p = 0.003]. HbA1c improved significantly after treatment with acarbose or glibenclamide. However, only treatment with acarbose significantly improved glucose excursions. The dawn phenomenon decreased significantly only in patients treated with acarbose (from 35.9 ± 15.7–28.3 ± 16.5 mg/dl, p = 0.037), but not in those treated with glibenclamide (from 35.9 ± 20.6–34.6 ± 17.0 mg/dl, p = 0.776). Conclusion: Glucose excursions were independently associated with the dawn phenomenon in patients with T2D on metformin monotherapy. Both glucose excursions and the dawn phenomenon improved after treatment with acarbose, but not after treatment with glibenclamide.

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Kishimoto, M., Y. Yamasaki, M. Kubota, K. Arai, T. Morishima, R. Kawamori, and T. Kamada. "1,5-Anhydro-D-glucitol Evaluates Daily Glycemic Excursions in Well-Controlled NIDDM." Diabetes Care 18, no. 8 (August 1, 1995): 1156–59. http://dx.doi.org/10.2337/diacare.18.8.1156.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Lv, Yuan, Ling-Ling Zhu, and Gui-Hua Shu. "Relationship between Blood Glucose Fluctuation and Brain Damage in the Hypoglycemia Neonates." American Journal of Perinatology 35, no. 10 (February 14, 2018): 946–50. http://dx.doi.org/10.1055/s-0038-1626706.

Повний текст джерела

Анотація:

Objective To investigate the relationship between blood glucose fluctuation and brain damage in the hypoglycemia neonates. Study Design A retrospective study including all neonates hospitalized due to hypoglycemia from September 2013 to August 2016 was performed. All the 58 hypoglycemia infants were divided into two groups—the brain-damaged group and the nonbrain-damaged group, according to head magnetic resonance imaging and/or amplitude-integrated electroencephalogram. Relationship between glucose variability and brain damage and whether these variation indexes could act as early indicators for hypoglycemic brain damage were investigated. Results Of the 13 brain-damaged cases, the lowest blood glucose (LBG) level was lower, while duration of hypoglycemia was longer compared with the 45 nonbrain-damaged cases (p < 0.001). The largest amplitude of glycemic excursions, standard deviation of blood glucose, and mean amplitude of glycemic excursions (MAGE) of the brain-damaged group were higher (p < 0.001). Under receiver-operating characteristic curve, values of area under the curve of MAGE were 0.892, duration of hypoglycemia was 0.921, and LBG was 0.109 (p < 0.0001). Conclusion Brain damage of the hypoglycemia neonates relates not only with LBG and duration of hypoglycemia but also with the blood glucose variation indexes; MAGE and duration of hypoglycemia could act as predictors for brain damage.

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Zhang, Xiuzhen, Dan Xu, Ping Xu, Shufen Yang, Qingmei Zhang, Yan Wu, and Fengyi Yuan. "Metformin improves glycemic variability in adults with type 1 diabetes mellitus: an open-label randomized control trial." Endocrine Connections 10, no. 9 (September 1, 2021): 1045–54. http://dx.doi.org/10.1530/ec-21-0146.

Повний текст джерела

Анотація:

Introduction Metformin has been demonstrated to enhance cardioprotective benefits in type 1 diabetes (T1DM). Although glycemic variability (GV) is associated with increased risk of CVD in diabetes, there is a scarcity of research evaluating the effect of metformin on GV in T1DM. Objectives In the present study, the effects of adjuvant metformin therapy on GV and metabolic control in T1DM were explored. Patients and methods A total of 65 adults with T1DM were enrolled and subjected to physical examination, fasting laboratory tests, and continuous glucose monitoring, and subsequently randomized 1:1 to 3 months of 1000–2000 mg metformin daily add-on insulin (MET group, n = 34) or insulin (non-MET group, n = 31). After, baseline measurements were repeated. Results The mean amplitude of glycemic excursions was substantially reduced in MET group, compared with non-MET group (–1.58 (–3.35, 0.31) mmol/L vs 1.36 (–1.12, 2.24) mmol/L, P = 0.004). In parallel, the largest amplitude of glycemic excursions (–2.83 (–5.47, –0.06) mmol/L vs 0.45 (–1.29, 4.48) mmol/L, P = 0.004), the s.d. of blood glucose (–0.85 (–1.51, 0.01) mmol/L vs –0.14 (–0.68, 1.21) mmol/L, P = 0.015), and the coefficient of variation (–6.66 (–15.00, 1.50)% vs –1.60 (–6.28, 11.71)%, P = 0.012) all demonstrated improvement in the MET group, compared with the non-MET group. Significant reduction in insulin dose, BMI, and body weight was observed in patients in MET, not those in non-MET group. Conclusion Additional metformin therapy improved GV in adults with T1DM, as well as improving body composition and reducing insulin requirement. Hence, metformin as an adjunctive therapy has potential prospects in reducing the CVD risk in patients with T1DM in the long term.

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Marker, Arwen M., Amy E. Noser, Mark A. Clements, and Susana R. Patton. "Shared Responsibility for Type 1 Diabetes Care Is Associated With Glycemic Variability and Risk of Glycemic Excursions in Youth." Journal of Pediatric Psychology 43, no. 1 (May 25, 2017): 61–71. http://dx.doi.org/10.1093/jpepsy/jsx081.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

WU, Di, Chun-xiu GONG, Xi MENG, and Qiu-lan YANG. "Correlation between blood glucose fluctuations and activation of oxidative stress in type 1 diabetic children during the acute metabolic disturbance period." Chinese Medical Journal 126, no. 21 (November 5, 2013): 4019–22. http://dx.doi.org/10.3760/cma.j.issn.0366-6999.20131841.

Повний текст джерела

Анотація:

Background Studies have shown that complications in type 1 diabetes mellitus (T1DM) in children are mainly due to oxidative stress (OS). Lipid peroxidation is the main marker of OS and iso-prostaglandin is a reliable biomarker of lipid peroxidation in type 2 diabetes mellitus (T2DM). However, there have been few studies on OS in T1DM children with hyperglycemia and glucose fluctuations. Methods We prospectively enrolled 23 newly diagnosed T1DM patients and 23 age and sex matched healthy controls in Beijing Children's Hospital from May 2010 to January 2011. They were treated with continuous subcutaneous insulin injection (CSII) and monitored by continuous glucose monitoring system (CGMS). Twenty-four-hour urine samples were collected to measure the concentration of 8-iso prostaglandin F2α (8-isoPGF2α). Samples taken from diabetic children were collected at days 8 to 10 after insulin treatment. Intraday glucose fluctuations were assessed by mean amplitude of glucose excursions (MAGE), largest amplitude of glycemic excursions (LAGE), standard deviation of blood glucose (SDBG) and number of glycemic excursions (NGE). The correlations between glucose parameters and the index of oxidative stress were analyzed. Results Urine 8-isoPGF2α in the T1DM group was higher than that in the control group ((967.70±412.68) ng vs. (675.23±354.59) ng, P=0.019). There was a correlation between urine 8-isoPGF2α level and MAGE (r=0.321, P=0.039), a significant correlation between low-density lipoprotein and urine 8-isoPGF2α level (r=0.419, P=0.03). There was no significant correlation between urine 8-isoPGF2α level and blood pressure, glycosylated hemoglobin (HbA1c), fasting C-peptide or other lipid indices. Conclusion A correlation between urine 8-isoPGF2α levels and MAGE and low-density lipoprotein was found in children newly diagnosed with T1DM.

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Al-Ozairi, Ebaa, Abeer El Samad, Jumana Al Kandari, Etab Taghadom, Safwaan Adam, Carel le Roux, and Akheel A. Syed. "Continuous Glucose Monitoring of Glycemic Variability During Fasting Post-Sleeve Gastrectomy." Obesity Surgery 30, no. 10 (July 17, 2020): 3721–29. http://dx.doi.org/10.1007/s11695-020-04505-4.

Повний текст джерела

Анотація:

Abstract Introduction Day-long fasting creates considerable metabolic stress that poses challenges in people with diabetes and those who have undergone bariatric surgery. Clinical knowledge of glucose fluctuations and the risks for such patients during fasting is limited. Objectives This study examined the effect of intermittent fasting on glucose excursions, hypoglycemia, and hyperglycemia in people with or without diabetes who had sleeve gastrectomy compared with healthy individuals. Methods This open-label, prospective study compared interstitial glucose profiles measured with continuous glucose monitoring system for 72 h during fasting and non-fasting periods between four groups comprising 15 participants each: people with obesity and medicine-treated type 2 diabetes (T2D) only, obesity and T2D treated with sleeve gastrectomy, obesity without T2D treated with sleeve gastrectomy, and healthy, normal-weight non-diabetic controls. Results The mean 72-h glucose concentration was significantly lower during the fasting period for all groups (p ≤ 0.041), with the highest glucose concentrations in the medicine-treated T2D-only group and the lowest concentrations in the sleeve gastrectomy in non-T2D group. The mean glucose profiles of all the groups showed a marked increase in interstitial glucose on breaking the fast, which was exaggerated in the two diabetes groups. The mean amplitude of glycemic excursions did not differ significantly within each group between fasting and non-fasting. No significant difference was noted in the fraction of time in the hypoglycemic range between the fasting and non-fasting periods in any group. Conclusion Intermittent fasting had no adverse effect on glycemic control in people with or without diabetes who had undergone sleeve gastrectomy.

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Palumbo, P. J. "Glycemic Control, Mealtime Glucose Excursions, and Diabetic Complications in Type 2 Diabetes Mellitus." Mayo Clinic Proceedings 76, no. 6 (June 2001): 609–18. http://dx.doi.org/10.4065/76.6.609.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Yoshioka, K., S. Yokoo, and T. Yoshida. "The efficacy of voglibose on glycemic excursions in non-insulin-treated NIDDM patients." Diabetes Care 21, no. 7 (July 1, 1998): 1206–7. http://dx.doi.org/10.2337/diacare.21.7.1206.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Yoshioka, K., S. Yokoo, and T. Yoshida. "The Efficacy of Voglibose on Glycemic Excursions in Non-Insulin-Treated NIDDM Patients." Diabetes Care 21, no. 7 (July 1, 1998): 1206. http://dx.doi.org/10.2337/diacare.21.7.1206a.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Beato-Víbora, Pilar I., and Francisco J. Arroyo-Díez. "Differences in the Mean Amplitude of Glycemic Excursions Calculated by Two Automated Methods." Diabetes Technology & Therapeutics 16, no. 2 (February 2014): 123–24. http://dx.doi.org/10.1089/dia.2013.0195.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Palumbo, P. J. "Glycemic Control, Mealtime Glucose Excursions, and Diabetic Complications in Type 2 Diabetes Mellitus." Mayo Clinic Proceedings 76, no. 6 (June 2001): 609–18. http://dx.doi.org/10.1016/s0025-6196(11)62412-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Ida, Satoshi, Ryutaro Kaneko, Kanako Imataka, Kaoru Okubo, Yoshitaka Shirakura, Kentaro Azuma, Ryoko Hujiwara, Hiroka Takahashi, and Kazuya Murata. "Effects of Flash Glucose Monitoring on Dietary Variety, Physical Activity, and Self-Care Behaviors in Patients with Diabetes." Journal of Diabetes Research 2020 (April 9, 2020): 1–7. http://dx.doi.org/10.1155/2020/9463648.

Повний текст джерела

Анотація:

The aim of this study was to evaluate the effects of flash glucose monitoring on dietary variety, physical activity, and self-care behavior in patients with diabetes. This study included outpatients with diabetes using insulin who presented at the Department of Diabetes and Metabolism of the Ise Red Cross Hospital. Before initiating flash glucose monitoring and 12 weeks after its initiation, blood glucose-related parameters were assessed and self-administered questionnaires were completed (Dietary Variety Score (DVS), the International Physical Activity Questionnaire (IPAQ), the Summary of Diabetes Self-Care Activities Measure (SDSCA), and the Diabetes Treatment Satisfaction Questionnaire (DTSQ)) and compared between the two time points. We analyzed 42 patients with type 1 diabetes mellitus and 48 patients with type 2 diabetes mellitus. In patients with type 2 diabetes mellitus, but not type 1 diabetes mellitus, there was an increase in moderate/high category scores for IPAQ (P<0.001) and for treatment satisfaction reported via DTSQ. Furthermore, in patients with type 2 diabetes mellitus, the glycemic excursion index improved significantly and HbA1c decreased significantly (from 7.7 (1.2) to 7.4 (0.8), P=0.025). Results showed that standard deviation and mean amplitude of glycemic excursions significantly decreased in patients with type 1 diabetes mellitus (from 71.2 (20.4) to 66.2 (17.5), P=0.033 and from 124.6 (31.9) to 108.1 (28.4), P<0.001, respectively). Flash glucose monitoring is a useful tool to improve physical activity in patients with type 2 diabetes.

Стилі APA, Harvard, Vancouver, ISO та ін.

Статті в журналах з теми "Glycemic excursions"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями